BACKGROUND: Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of @entity5 in @entity1 with @entity5345 or @entity2674 mutations are limited. We investigated whether this procedure reduces the risk of @entity5 of the coelomic epithelium and breast in @entity1 who carry such mutations. METHODS: A total of 551 @entity1 with disease-associated germ-line @entity5345 or @entity2674 mutations were identified from registries and studied for the occurrence of @entity5344 . We determined the incidence of @entity43 in 259 @entity1 who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not undergone the procedure. In a subgroup of 241 @entity1 with no history of @entity0 or prophylactic mastectomy, the incidence of @entity0 was determined in 99 @entity1 who had undergone bilateral prophylactic oophorectomy and in 142 matched controls. The length of postoperative follow-up for both groups was at least eight years. RESULTS: Six @entity1 who underwent prophylactic oophorectomy (2.3 percent) received a diagnosis of @entity43 at the time of the procedure; two @entity1 (0.8 percent) received a diagnosis of @entity1377 3.8 and 8.6 years after bilateral prophylactic oophorectomy. Among the controls, 58 @entity1 (19.9 percent) received a diagnosis of @entity43 , after a mean follow-up of 8.8 years. With the exclusion of the six @entity1 whose @entity5 was diagnosed at surgery, prophylactic oophorectomy significantly reduced the risk of @entity5 (hazard ratio, 0.04; 95 percent confidence interval, 0.01 to 0.16). Of 99 @entity1 who underwent bilateral prophylactic oophorectomy and who were studied to determine the risk of @entity0 , @entity0 developed in 21 (21.2 percent), as compared with 60 (42.3 percent) in the control group (hazard ratio, 0.47; 95 percent confidence interval, 0.29 to 0.77). CONCLUSIONS: Bilateral prophylactic oophorectomy reduces the risk of @entity5 and @entity0 in @entity1 with @entity5345 or @entity2674 mutations.

Prophylactic oophorectomy in carriers of XXXX or @entity2674 mutations.

@entity1 :: ('9606', 'Species') :: ['women'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'stage I ovarian cancer'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary serous peritoneal carcinoma'] @entity5344 :: ('MESH:D061325', 'Disease') :: ['ovarian and breast cancer'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['gynecologic cancer', 'cancers', 'cancer', 'coelomic epithelial cancer'] @entity5345 :: ('672', 'Gene') :: ['BRCA1'] @entity2674 :: ('675', 'Gene') :: ['BRCA2']
@entity5345 :: (672,Gene) :: ['BRCA1']
